PAR DRUGS AND CHEM LTD Valuation
PAR · Healthcare · Current price ₹104.93
Is PAR DRUGS AND CHEM LTD undervalued?
DocStoX estimates the fair value of PAR DRUGS AND CHEM LTD at ₹170 per share, versus the current market price of ₹105. That puts the stock about +61.7% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹99), Relative P/E (₹323), Graham floor (₹148). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹99 (bear) to ₹170 (base) to ₹323 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
PAR DRUGS AND CHEM LTD trades at a P/E of 9.7x and a P/B of 1.0x, with a dividend yield of 1.4%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on PAR DRUGS AND CHEM LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.